PT-141
Also known as: Bremelanotide, Vyleesi
PT-141 (bremelanotide) is a melanocortin receptor agonist studied for sexual dysfunction. As Vyleesi it is approved in the US for a specific condition, but it is not generally approved for human use in Australia.
- Category
- Sexual Health
- Reported half-life
- Reported ~2-3 hours (varies by study and route)
- Common forms
- Approved injectable in some markets (Vyleesi), Investigational preparations described in research
- Research status
- Bremelanotide (Vyleesi) is approved in the US for a specific condition (hypoactive sexual desire disorder in certain women). It is not generally approved for human use in Australia.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in research to influence sexual desire via central pathways
- Studied (as Vyleesi) for a specific form of low sexual desire in women
- Reported to act on the nervous system rather than the vascular system
How it is reported to work
PT-141 is described as a synthetic analogue related to melanocyte-stimulating hormone that activates melanocortin receptors (notably MC4R) in the central nervous system. Unlike vascular-acting agents, it is proposed to influence sexual response through brain pathways. These descriptions derive from clinical research on bremelanotide.
Background
PT-141, also called bremelanotide, is a melanocortin receptor agonist investigated for sexual dysfunction. In some markets it is sold as Vyleesi for a specific condition. This page is educational information, not medical advice, and does not recommend or encourage use.
What the research shows
Clinical research on bremelanotide is reported to show effects on sexual desire through central nervous system pathways. Outside its specific approved indication elsewhere, broader claims are not established.
| Feature | Reported status |
|---|---|
| Mechanism | Central melanocortin (MC4R) |
| Approved indication (US) | Specific, narrow |
| Australian general-use approval | None |
What people use it for (reported)
Online discussions report interest in PT-141 for libido and sexual response. These are anecdotal reports, not validated outcomes, and should not be read as established facts or as a recommendation. The presence of an approved product in one market for one narrow condition does not mean broader self-directed use is supported by evidence or by regulators, and this page does not encourage any such use.
Things to be aware of
PT-141 is not generally approved for human use in Australia. Reported study side effects include nausea and transient blood pressure changes, and grey-market product identity cannot be verified.
If you have a sexual-health concern, the appropriate step is to consult a qualified healthcare professional. This article does not endorse obtaining or using PT-141.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in research to increase sexual desire via central nervous system pathways
- Studied (as Vyleesi) for a specific form of low sexual desire in women
- Reported to act centrally rather than on blood flow, unlike vascular agents
- Reported onset within hours of a single dose in studies
Common side effects
- Reported nausea, sometimes significant
- Reported flushing and headache
- Reported transient increases in blood pressure
- Reported injection-site reactions
- Reported temporary skin darkening with repeated use
Rare / serious side effects
- Reported priapism (prolonged, painful erection) with overuse
- Reported pronounced or sustained blood-pressure changes
- Reported fainting or severe nausea with vomiting
- Reported focal hyperpigmentation (darkened patches) on the face or gums
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of PT-141. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported nausea, sometimes severe, from doses taken above researched amounts
- Reported blood-pressure changes that may be hazardous in those with cardiovascular conditions
- Reported priapism with frequent or overuse, which can be a medical emergency
- Reported repeated dosing for recreational enhancement outside any approved indication
- Reported use of unverified self-sourced product of unknown purity
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Reported onset is within hours of a dose, with effects described as acute rather than cumulative.
First effects
reported within hours of a single dose
Noticeable change
reported with repeated dosing over a few weeks
Clear results
reported subjective pattern over an extended period; not advice
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take PT-141. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Reported as subcutaneous injection (the approved Vyleesi form is a 1.75 mg auto-injector) |
|---|---|
| Typical reported dose | Reported around 1-2 mg per dose; the approved Vyleesi auto-injector delivers 1.75 mg |
| Frequency | Reported as needed before activity; the approved label notes a maximum of one dose per 24 hours and a limited number of doses per week |
| Cycle length | Used on an as-needed basis rather than in cycles |
Reported reconstitution (mg → units)
For vialled forms, reported example: a 10 mg vial plus 5 mL bacteriostatic water gives 2 mg/mL. A reported 1.75 mg dose is about 0.875 mL, which is roughly 87.5 units on a U-100 insulin syringe. The approved Vyleesi auto-injector is pre-filled and not reconstituted.
Work out the units for your vial → CalculatorCommonly reported as occasional as-needed dosing ahead of activity rather than continuous use; this is reported information, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported together as related melanocortin agonists, though this compounds side-effect overlap
Reported alongside it for interest in reproductive and sexual pathways
Reported together anecdotally for interest in libido and arousal pathways
Safety notes
PT-141 is not generally approved for human use in Australia, and reported side effects in studies have included nausea and transient blood pressure changes. Self-sourced product purity cannot be verified. Anyone with a sexual-health concern should consult a qualified healthcare professional.